The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. - Wikidata - awgldk - TriplyDB

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

http://www.wikidata.org/entity/Q38205588

about

Clinically and pharmacologically relevant interactions of antidiabetic drugs Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes Adverse Effects of GLP-1 Receptor Agonists Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury Dapagliflozin in patients with type 2 diabetes mellitus.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Vildagliptin-induced acute lung injury: a case report.Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.SGLT2 inhibitors: are they safe?Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

P2860

Q26752468-DF267B86-C75F-4B16-A77F-0FB56E491B13 Q26785454-A723658D-5A91-4D04-8E56-6D3F19C9BDED Q26801346-D960F760-CB59-4963-B370-5BE04BB7119C Q28066209-0D034AD7-3338-437B-8E9F-BA4F5D99E9AC Q33826729-9D3CD4DA-0990-44A6-890D-F2C8E81F8886 Q35064363-1DB10422-B628-4A3D-A06E-D52C8C57655D Q38658251-09331ABD-3264-4195-8C6B-35A49A7F6555 Q39000587-9EBB81AE-1492-4B2A-ABF6-0235E9EAA244 Q40577527-D654AB00-2E78-4663-9D9C-83883F94758E Q41090670-0ED62A0A-0E2B-4D93-B08F-2CA9E865BB79 Q47137374-87E58E4C-05A6-428B-BCD0-C86CCDB48A3D Q47293312-FCEFFF67-E429-45D8-93BB-40F43BD70605 Q47642298-26DA268A-254D-4229-9743-1FAF0C3E5BF4 Q51311444-EB6548C6-5682-4BAF-997E-30A5A8408597 Q55340870-10FE6506-3F54-4961-A391-518AB84CC608

P2860

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

http://www.wikidata.org/entity/Q38205588

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

@en

type

label

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

@en

prefLabel

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

@en

P1433

Q38205588-28FF00F1-3614-44D2-9E3E-837426B4CD8B

P1476

Q38205588-78481DA9-EC1F-46A4-9D4D-A922D0781A47

P2093

Q38205588-C096A6B0-CBFD-4EE8-87DC-228431C52EDE

P2860

Q38205588-046D8A76-2DDD-4C1C-9C30-A8CC96BE95C0

Q38205588-04A1A57B-3506-4A55-8649-9C49BCFCD01C

Q38205588-072472D8-4FC8-4DBF-BA23-430EF76460CD

Q38205588-076AAF70-58F4-4A95-9D9D-1A7B78B00800

Q38205588-077E7CDB-A4BF-4F53-B065-4BD8B1090441

Q38205588-09872A1D-C7AE-4DA9-97E1-4B26010AF9DB

Q38205588-0B7439C0-B881-4131-860A-4746B579FCF9

Q38205588-0E01B86B-BF0F-45AC-94CB-27B8C263490B

Q38205588-0E5612C0-A075-4932-ACE8-B0F24D262FA2

Q38205588-0EC48146-14AE-402B-B3B7-88AD33F249DD

P304

Q38205588-439D19AB-A992-4543-A6C8-A59D18FCF174

P31

Q38205588-5C1E709C-46E9-425A-9FFE-26A1472A1549

P356

Q38205588-1DE6870E-12B3-4B3F-909C-D94D1CFF70BD

P407

Q38205588-CA16B56B-101B-4140-9B97-B3A91B4E2E55

P433

Q38205588-C9049167-B9DE-41F1-8411-DCEDBF44CEC4

P478

Q38205588-4A18FA34-8160-487A-A069-73B4FAD05B15

P50

Q38205588-68925C48-C861-4816-AF94-32027860BEA6

Q38205588-D139F52A-3016-4393-B5EB-9C4D4ABBCC77

P577

Q38205588-E5853A5B-C590-4B85-8D9B-D0CD72390B16

P698

Q38205588-232FB49F-79B0-4D0E-9A00-A4FF4863F06B

P356

17425255.2014.907274

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

@en

P2093

Vasilios G Athyros

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase

Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

P304

787-812

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2014.907274

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Theodosios D. Filippatos

P577

2014-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24746233

http://www.w3.org/2001/XMLSchema#string